New vaccine combo targets tough pancreatic cancer
NCT ID NCT07231094
First seen Nov 17, 2025 · Last updated May 25, 2026 · Updated 28 times
Summary
This early-phase trial tests a new tumor vaccine (SapDM275) combined with standard chemotherapy (AG regimen) in 13 people with metastatic pancreatic cancer who have not had prior treatment. The goal is to see if the combination is safe and can help control the disease. Participants receive the vaccine as a shot and continue treatment until the cancer worsens or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Third Xiangya Hospital of Central South University
Hunan, Changsha, 410000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.